Also listed on Graceway Pharmaceuticals, LLC, an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Oct 12, 2027 · High confidence
20-year base term ends Oct 12, 2027
Held by Thirona Bio, Inc.
Filed May 20, 2011 as application 13/112,520 · Granted Jun 4, 2013
Base term, 20 years from filing
Today
2007
2027
Clock starts
Oct 12, 2007
Oct 12, 2007
Term ends
Oct 12, 2027
Oct 12, 2027
Granted
Jun 4, 2013
Jun 4, 2013
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 7,964,612, to Oct 12, 2027. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 12, 2007, when application 11/871,311, the earliest non-provisional in its chain, was filed (this one was filed May 20, 2011) | Oct 12, 2027 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 7,964,612) | resolves to Oct 12, 2027, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Oct 12, 2027 | High confidence |
This family
| US 7,964,612 | In force Aug 2029 | Aug 2029 |
| US 8,455,512 | this patent Oct 2027 | Oct 2027 |
| US 9,090,625 | In force Oct 2027 | Oct 2027 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 27, 2011 Reel 26659, frame 186 | Pfizer Inc.; Warner Lambert LLC | Graceway Pharmaceuticals, LLC | Assignment of Assignor's Interest |
| Jul 27, 2011 Reel 26659, frame 205 | Barrett, Stephen D.; Boys, Mark L.; Chen, Huifen; Kramer, James B. | Pfizer Inc. | Assignment of Assignor's Interest |
| Dec 13, 2011 Reel 27370, frame 813 | Graceway Pharmaceuticals, LLC | Medicis Pharmaceutical Corporation | Assignment of Assignor's Interest |
| Apr 24, 2013 Reel 30281, frame 433 | Medicis Pharmaceutical Corporation | Goldman Sachs Lending Partners LLC | Security Agreement |
| Sep 25, 2013 Reel 31280, frame 766 | Medicis Pharmaceutical Corporation | Thesan Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jan 10, 2014 Reel 31944, frame 190 | Goldman Sachs Lending Partners LLC | Medicis Pharmaceutical Corporation | Release of Security Interest |
| Jan 9, 2015 Reel 34749, frame 689 | Goldman Sachs Lending Partners, LLC | Barclays Bank PLC, as Successor Agent | Notice of Succession of Agency |
| Jan 29, 2018 Reel 45177, frame 26 | Goldman Sachs Lending Partners LLC | Barclays Bank PLC, as Successor Agent | Corrective Assignment to Correct the Inadvertent Patent Numbers Added Previously Recorded at Reel: 034749 Frame: 0689. Assignor(S) Hereby Confirms the Assignment . |
| May 11, 2018 Reel 45777, frame 324 | Thesan Pharmaceuticals, Inc. | FBM Therapeutics, LLC | Assignment of Assignor's Interest |
| Apr 14, 2021 Reel 56830, frame 556 | FBM Therapeutics, LLC | FBM Therapeutics, Inc. | Entity Conversion |
| Apr 15, 2021 Reel 56028, frame 290 | FBM Therapeutics, Inc. | Thirona Bio, Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Oct 2027
Term ends Oct 12, 2027. No further fees fall due before then
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 7,964,612, ends no earlier than this term, so it caps nothing.
Citations
5
later US patents cite this one
That is below the median of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.